Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ramirez, Michael ^a,b   Rajaram, Satwik ^a,b   Steininger, Robert J ^b   Osipchuk, Daria ^a   Roth, Maike A ^a   Morinishi, Leanna S ^a   Evans, Louise ^a   Ji, Weiyue ^a   Hsu, Chien Hsiang ^a   Thurley, Kevin ^a   Wei, Shuguang ^c   Zhou, Anwu ^c   Koduru, Prasad R ^c   Posner, Bruce A ^c   Wu, Lani F ^a,b   Altschuler, Steven J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CAPMATINIB; CRIZOTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PIMASERTIB; RAPAMYCIN; SELUMETINIB; ANTINEOPLASTIC AGENT;

CANCER; CELLS AND CELL COMPONENTS; DRUG RESISTANCE; GENETIC ANALYSIS; GENOME;

ARTICLE; CANCER RESISTANCE; DRUG SCREENING; EXOME; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MOUSE; MUTATION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; TUMOR CELLS, CULTURED;

EID: 84958999430     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10690     Document Type: Article

References (41)

1. Glickman, M. S., Sawyers, C. L. Converting cancer therapies into cures: lessons from infectious diseases. Cell 148, 1089-1098 (2012).
2. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
3. Marusyk, A., Polyak, K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105-117 (2010).
4. Bean, J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104, 20932-20937 (2007).
5. Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440-448 (2015).
6. Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
7. Lin, L., Bivona, T. G. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC Patients. Chemother. Res. Pract. 2012, 817297 (2012).
8. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
9. Dawson, C. C., Intapa, C., Jabra-Rizk, M. A. 'Persisters': survival at the cellular level. PLoS Pathog. 7, e1002121 (2011).
10. Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., Leibler, S. Bacterial persistence as a phenotypic switch. Science 305, 1622-1625 (2004).
11. Lantermann, A. B. et al. Inhibition of casein kinase 1 alpha prevents acquired drug resistance to erlotinib in EGFR-mutant non-small cell lung cancer. Cancer Res. 75, 4937-4948 (2015).
12. Banelli, B. et al. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle 14, 3418-3429 (2015).
13. Tetsu, O., Phuchareon, J., Eisele, D. W., Hangauer, M. J., McCormick, F. AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol. Res. 102, 132-137 (2015).
14. Camidge, D. R., Pao, W., Sequist, L. V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473-481 (2014).
15. Ono, M. et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3, 465-472 (2004).
16. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
17. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
18. Zhou, W. et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074 (2009).
19. Ou, S. H. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol. 83, 407-421 (2012).
20. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
21. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
22. Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014).
23. Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Grey, J. W., Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9, 708-714 (2013).
24. Thorne, C. A. et al. GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors. Nat. Chem. Biol. 11, 58-63 (2015).
25. Jia, P. et al. Next-generation sequencing of paired tyrosine kinase inhibitorsensitive and-resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 23, 1434-1445 (2013).
26. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
27. Aaron, N. H. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. doi:10.1038/nm.4040 (2016).
28. Ercan, D. et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2, 934-947 (2012).
29. Eberlein, C. A. et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 75, 2489-2500 (2015).
30. Simon, R. et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 61, 4514-4519 (2001).
31. Atefi, M. et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 6, e28973 (2011).
32. Niederst, M. J., Engelman, J. A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 6, re6 (2013).
33. Bader, A. G., Kang, S., Vogt, P. K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl Acad. Sci. USA 103, 1475-1479 (2006).
34. Chaft, J. E. et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther. 11, 485-491 (2012).
35. Moldovan, G. L. et al. DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol. Cell Biol. 30, 1088-1096 (2010).
36. Iadevaia, S., Lu, Y., Morales, F. C., Mills, G. B., Ram, P. T. Identification of optimal drug combinations targeting cellular networks: integrating phosphoproteomics and computational network analysis. Cancer Res. 70, 6704-6714 (2010).
37. Frank, S. A., Rosner, M. R. Nonheritable cellular variability accelerates the evolutionary processes of cancer. PLoS Biol. 10, e1001296 (2012).
38. Nguyen, T. T. et al. Robust dose-response curve estimation applied to high content screening data analysis. Source Code Biol. Med. 9, 27 (2014).
39. Li, H., Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
40. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
41. Sathirapongsasuti, J. F. et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654 (2011).